Clinical population pharmacokinetics and toxicodynamics of linezolid.
about
Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.Basis for selecting optimum antibiotic regimens for secondary peritonitis.Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.Risk factors associated with high linezolid trough plasma concentrations.Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically-relevant Concentrations in cultured Human HL-60 promyelocytes and THP-1 monocytes.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options).Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects.A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy.
P2860
Q33439246-3A24A6BC-A3A2-4BD5-B570-2C699B90DFC2Q38391120-B3B57764-F72F-4F4D-999E-A38F106027D7Q38633450-2DBD38EF-49C1-4D53-84BA-D21A7C51F602Q38777085-07DB3C19-B739-4C3B-9DD6-8BD228FF5C0BQ38837353-5BB906A3-14C8-41CC-9893-DABBFC9487ADQ39278957-FFA4EBCE-0D8F-47D3-94A1-642488837C8AQ40683242-E6CCE572-CB61-4B8B-988D-519460BF2919Q47269635-025908D9-9469-4988-964D-0991CFFF32CCQ47396324-15943E78-E21E-4C64-8ED9-48075F44143BQ47611899-09FD9EED-6D6E-401D-8EAC-297AC8B1437EQ48108947-C9189DFD-392F-4AB4-B6C7-F797272065D0Q50082653-DD1816C5-F132-4043-B075-AD5E3CB9D4F1Q50719557-923B347C-169C-4E83-84E1-03C6FEE5CF4EQ52854660-4253EEB2-6121-4780-98A0-E97EAA893F31
P2860
Clinical population pharmacokinetics and toxicodynamics of linezolid.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical population pharmacokinetics and toxicodynamics of linezolid.
@ast
Clinical population pharmacokinetics and toxicodynamics of linezolid.
@en
type
label
Clinical population pharmacokinetics and toxicodynamics of linezolid.
@ast
Clinical population pharmacokinetics and toxicodynamics of linezolid.
@en
prefLabel
Clinical population pharmacokinetics and toxicodynamics of linezolid.
@ast
Clinical population pharmacokinetics and toxicodynamics of linezolid.
@en
P2093
P2860
P356
P1476
Clinical population pharmacokinetics and toxicodynamics of linezolid.
@en
P2093
Alan Forrest
Blair Capitano
Craig R Rayner
Denis Spelman
Lauren M Boak
M Lindsay Grayson
Roger L Nation
Sharmila Khumra
P2860
P304
P356
10.1128/AAC.01885-13
P407
P577
2014-02-10T00:00:00Z